{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:31:21Z","timestamp":1791217881920,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Post-transplant lymphoproliferative disease (PTLD) is the most common malignancy complicating solid organ transplantation (SOT) in adults and children. PTLD encompasses a spectrum of histopathologic features and organ involvement, ranging from benign lymphoproliferation and infectious-mononucleosis like presentation to invasive neoplastic processes such as classical Hodgkin lymphoma. The predominant risk factors for PTLD are Epstein-Barr virus (EBV) serostatus at the time of transplant and the intensity of immunosuppression following transplantation; with EBV-negative recipients of EBV-positive donor organs at the highest risk. In children, PTLD commonly presents in the first two years after transplant, with 80% of cases in the first year, and over 90% of cases associated with EBV-positive B-cell proliferation. Though pediatric kidney transplant recipients are at lower risk (1\u20133%) for PTLD compared to their other SOT counterparts, there is still a significant risk of morbidity, allograft failure, and an estimated 5-year mortality rate of up to 50%. In spite of this, there is no consensus for monitoring of at-risk patients or optimal management strategies for pediatric patients with PTLD. Here we review pathogenesis and risk factors for the development of PTLD, with current practices for prevention, diagnosis, and management of PTLD in pediatric kidney transplant recipients. We also highlight emerging concepts, current research gaps and potential future developments to improve clinical outcomes and longevity in these patients.<\/jats:p>","DOI":"10.3389\/fped.2022.1087864","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T06:20:25Z","timestamp":1670394025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Post-transplant lymphoproliferative disease after pediatric kidney transplant"],"prefix":"10.3389","volume":"10","author":[{"given":"Rosanna","family":"Fulchiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJM199012203232510","article-title":"Cancers complicating organ transplantation","volume":"323","author":"Penn","year":"1990","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.transproceed.2008.12.020","article-title":"De novo malignancy after solid organ transplantation in children","volume":"41","author":"Debray","year":"2009","journal-title":"Transplant Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00007890-200104270-00010","article-title":"Risk factors for posttransplant lymphoproliferative disorder (ptld) in pediatric kidney transplantation: a report of the north American pediatric renal transplant cooperative study (NAPRTCS)1","volume":"71","author":"Dharnidharka","year":"2001","journal-title":"Transplantation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/TP.0000000000002378","article-title":"Elevated risk of cancer after solid organ transplant in childhood: a population-based cohort study","volume":"103","author":"Kitchlu","year":"2019","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/814973","article-title":"Posttransplant lymphoproliferative disease after pediatric solid organ transplantation","volume":"2013","author":"Mynarek","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.V87.6.2594.bloodjournal8762594","article-title":"The development of cellular immunity to epstein-barr virus after allogeneic bone marrow transplantation","volume":"87","author":"Lucas","year":"1996","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of epstein-barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/00007890-199910150-00017","article-title":"Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression","volume":"68","author":"Ellis","year":"1999","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/children8080661","article-title":"Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN transplantChild healthcare working group survey","volume":"8","author":"Baker","year":"2021","journal-title":"Children"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","article-title":"Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management","volume":"2","author":"Nijland","year":"2016","journal-title":"Transplant Direct"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with epstein-barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"Destefano","year":"2018","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1399-3046.2012.01731.x","article-title":"Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - A national study","volume":"16","author":"Cleper","year":"2012","journal-title":"Pediatr Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/petr.12167","article-title":"Post-transplant lymphoproliferative disorder: no relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients","volume":"17","author":"Longmore","year":"2013","journal-title":"Pediatr Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-143333","article-title":"Post-Transplant lymphoproliferative disorder after renal transplant in the pediatric population: a systematic review","volume":"136","author":"Haider","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MOT.0b013e3283186ba9","article-title":"Epstein-Barr virus, rapamycin, and host immune responses","volume":"13","author":"Krams","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1743-422X-11-110","article-title":"Inhibition of mTORC1 inhibits lytic replication of epstein-barr virus in a cell-type specific manner","volume":"11","author":"Adamson","year":"2014","journal-title":"Virol J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1399-3046.2005.00324.x","article-title":"Sirolimus in pediatric patients: results in the first 6 months post-renal transplant","volume":"9","author":"Hymes","year":"2005","journal-title":"Pediatr Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/BF00867683","article-title":"FK506 In pediatric kidney transplantation\u2014primary and rescue experience","volume":"9","author":"Shapiro","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00007890-199901270-00020","article-title":"Pediatric renal transplantation under tacrolimus-based immunosuppression1","volume":"67","author":"Shapiro","year":"1999","journal-title":"Transplantation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00467-017-3826-x","article-title":"State-of-the-art immunosuppression protocols for pediatric renal transplant recipients","volume":"34","author":"Pape","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0146523","DOI":"10.1371\/journal.pone.0146523","article-title":"Steroid avoidance or withdrawal regimens in paediatric kidney transplantation: a meta-analysis of randomised controlled trials","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1128\/CMR.00006-09","article-title":"Using epstein-barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder","volume":"23","author":"Gulley","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","article-title":"Frequent monitoring of epstein-barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients","volume":"97","author":"Stevens","year":"2001","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/00007890-200008270-00010","article-title":"Predictive negative value of persistent low epstein-barr virus viral load after intestinal transplantation in children","volume":"70","author":"Green","year":"2000","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trre.2016.12.001","article-title":"Epstein-Barr virus and renal transplantation","volume":"31","author":"Le","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00467-017-3627-2","article-title":"Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients","volume":"32","author":"Colombini","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood.V84.3.972.972","article-title":"Increased levels of circulating epstein-barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients","volume":"84","author":"Riddler","year":"1994","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1097\/00007890-199812270-00006","article-title":"Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients","volume":"66","author":"McDiarmid","year":"1998","journal-title":"Transplantation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e203","article-title":"Post-Transplant lymphoproliferative diseases in pediatric kidney allograft recipients with epstein-barr virus viremia","volume":"34","author":"Hyun","year":"2019","journal-title":"J Korean Med Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and Acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am J Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of epstein-barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"Aldabbagh","year":"2017","journal-title":"Am J Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080864","article-title":"Progress in prophylactic and therapeutic EBV vaccine development based on molecular characteristics of EBV target antigens","volume":"11","author":"Rozman","year":"2022","journal-title":"Pathogens"},{"key":"B44","year":""},{"key":"B45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein-Barr virus infection and posttransplant lymphoproliferative disorder","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1148\/radiology.217.1.r00oc3816","article-title":"Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features","volume":"217","author":"Pickhardt","year":"2000","journal-title":"Radiology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00007890-199501000-00016","article-title":"Central nervous system lymphomas in organ allograft recipients","volume":"59","author":"Penn","year":"1995","journal-title":"Transplantation"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1086\/320903","article-title":"Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients","volume":"33","author":"Preiksaitis","year":"2001","journal-title":"Clin Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD task force and the mayo clinic organized international consensus development meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-3-319-13150-4_13","article-title":"Post-transplant lymphoproliferative disorders","volume":"165","author":"Singavi","year":"2015","journal-title":"Cancer Treat Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14268","article-title":"Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center","volume":"26","author":"Ramos-Gonzalez","year":"2022","journal-title":"Pediatr Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder\u2605","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood.V104.11.746.746","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial","volume":"104","author":"Webber","year":"2004","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14042","article-title":"Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients","volume":"25","author":"Zierhut","year":"2021","journal-title":"Pediatr Transplant"},{"key":"B56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/01.tp.0000258647.50947.78","article-title":"Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab","volume":"83","author":"Trappe","year":"2007","journal-title":"Transplantation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-Dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology group report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"key":"B60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-Transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/HS9.0000000000000226","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"3","author":"Dierickx","year":"2019","journal-title":"HemaSphere"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.34","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment","author":"Shahid","year":"2021","journal-title":"Cancer Drug Resistance"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/tri.14107","article-title":"EBV-Specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review","volume":"34","author":"Liu","year":"2021","journal-title":"Transpl Int"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e13133","DOI":"10.1111\/petr.13133","article-title":"Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children","volume":"22","author":"Chiou","year":"2018","journal-title":"Pediatr Transplant"},{"key":"B65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/CCO.0000000000000580","article-title":"Adoptive cell therapies for posttransplant infections","volume":"31","author":"Sutrave","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1375","article-title":"Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease\u2014a 20\u2009years\u2019 experience from Austria","volume":"4","author":"F\u00fcreder","year":"2021","journal-title":"Cancer Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13747","article-title":"Post transplant lymphoproliferative disorder risk factors in children: analysis of a 23-year single-institutional experience","volume":"24","author":"Bosse","year":"2020","journal-title":"Pediatr Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000350331","article-title":"Posttransplant lymphoproliferative disorder in pediatric patients","volume":"80","author":"Hussein","year":"2013","journal-title":"Pathobiology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00000658-200210000-00005","article-title":"Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience","volume":"236","author":"Jain","year":"2002","journal-title":"Ann Surg"},{"key":"B71","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS Or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/j.1600-6143.2004.00562.x","article-title":"Successful renal retransplantation after post-transplant lymphoproliferative disease","volume":"4","author":"Karras","year":"2004","journal-title":"Am J Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/ctr.12659","article-title":"Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder","volume":"30","author":"Rouphael","year":"2016","journal-title":"Clin Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00467-019-04284-w","article-title":"Biomarkers for PTLD diagnosis and therapies","volume":"35","author":"Martinez","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"150835","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin Dev Immunol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1087864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T06:20:28Z","timestamp":1670394028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1087864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":77,"alternative-id":["10.3389\/fped.2022.1087864"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1087864","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"article-number":"1087864"}}